Head to Head Contrast: Jupiter Neurosciences (JUNS) vs. The Competition

Jupiter Neurosciences (NASDAQ:JUNS) is one of 247 publicly-traded companies in the “MED – DRUGS” industry, but how does it weigh in compared to its peers? We will compare Jupiter Neurosciences to related companies based on the strength of its valuation, profitability, risk, dividends, analyst recommendations, institutional ownership and earnings.

Insider & Institutional Ownership

43.9% of shares of all “MED – DRUGS” companies are owned by institutional investors. 50.8% of Jupiter Neurosciences shares are owned by company insiders. Comparatively, 13.2% of shares of all “MED – DRUGS” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Jupiter Neurosciences and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Jupiter Neurosciences	N/A	-1,314.62%	-202.57%
Jupiter Neurosciences Competitors	-22,657.47%	-150.19%	-22.81%

Valuation & Earnings

This table compares Jupiter Neurosciences and its peers top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Jupiter Neurosciences	$20,000.00	-$8.65 million	-1.73
Jupiter Neurosciences Competitors	$1.16 billion	$98.20 million	-4.47

Jupiter Neurosciences’ peers have higher revenue and earnings than Jupiter Neurosciences. Jupiter Neurosciences is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Risk and Volatility

Jupiter Neurosciences has a beta of 2.8, meaning that its stock price is 180% more volatile than the S&P 500. Comparatively, Jupiter Neurosciences’ peers have a beta of -0.38, meaning that their average stock price is 138% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Jupiter Neurosciences and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jupiter Neurosciences	1	0	0	0	1.00
Jupiter Neurosciences Competitors	2845	4046	10318	468	2.48

As a group, “MED – DRUGS” companies have a potential upside of 51.70%. Given Jupiter Neurosciences’ peers stronger consensus rating and higher possible upside, analysts plainly believe Jupiter Neurosciences has less favorable growth aspects than its peers.

Summary

Jupiter Neurosciences peers beat Jupiter Neurosciences on 9 of the 13 factors compared.

About Jupiter Neurosciences

Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease. In addition, it is developing JNS109 for amyotrophic lateral sclerosis; JNS110 for traumatic brain injury/concussion; and JNS120 for covid-19 treatment. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. The company was founded in 2016 and is headquartered in Jupiter, Florida.